FDA Advisory Committee Recommends Warning for Gadolinium MRI Agents

Drug Industry Daily
A A
An FDA advisory committee voted 13-to-1 in favor of adding a warning about the risk of gadolinium retention to prescribing information for gadolinium-based contrast agents used in MRI scans.

To View This Article:

Login

Subscribe To Drug Industry Daily